Astragaloside-IV promotes autophagy via the Akt/mTOR pathway to improve cellular lipid deposition

Guo Liu,Ye-Hui Wang,Ting Zhang,Ya-Qiong Li,Xin-Yue Chen,Wei Dong,Wei Li,Qi-Xiang Miao,Wen-Bo Qiao,Hui-Qiang Tian,Shi-Long Yin
DOI: https://doi.org/10.1097/md.0000000000037846
IF: 1.6
2024-04-20
Medicine
Abstract:Nonalcoholic fatty liver disease (NAFLD) refers to a clinicopathological syndrome characterized by excessive accumulation of fat in hepatocytes caused by alcohol and other definite liver-damaging factors, and acquired metabolic stress liver injury that is closely related to insulin resistance and genetic predisposition, including nonalcoholic fatty liver disease or simple steatosis, nonalcoholic steatohepatitis, liver fibrosis, and liver cirrhosis. Eventually, hepatocellular carcinoma can develop without significant cirrhosis. [ 1 , 2 ] In recent years, the incidence and prevalence of NAFLD have increased rapidly worldwide, and are increasing annually among younger individuals. [ 3 , 4 ] However, there is no specific drug for preventing and treating nonalcoholic fatty liver disease. At present, the drugs used in clinical treatment for NAFLD include lipid-lowering drugs, peroxisome proliferator-activated receptor agonists, and hepatoprotective and anti-inflammatory drugs. However, most of them are not significantly effective and have remarkable side effects. Moreover, the US Food and Drug Administration did not approve any specific drug for treating NAFLD. [ 5 ] Therefore, a safe and effective novel therapeutic drug for NAFLD should be explored. Natural herbal medicines are characterized by complex compositions and have multiple targets. Thus, safer and more effective drugs for treating nonalcoholic fats can be developed.
medicine, general & internal
What problem does this paper attempt to address?